A clinical trial in patients with obesity and DM showed that chronic administration of a long-acting form of FGF21 caused a marked elevation of circulating adiponectin levels and an obvious reduction in blood levels of total and LDL-cholesterol [7]. The gene discussed is ADIPOQ; the disease is obesity due to melanocortin 4 receptor deficiency.